Stryker Corporation (SYK)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $117.88B
Last updated: Nov 17, 2026 at 11:06 AM ET
Stryker Corporation (SYK) Earnings: Report Dates and Results
Stryker (SYK) is expected to report earnings on Jan 27, 2027. In the quarter ended Sep 30, 2026, Stryker reported EPS of $3.52, below the $3.56 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SYK has an expected report date of Jan 27, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 13.2% above the $4.47 reported for the quarter ended Dec 31, 2025.
SYK Earnings Call
The latest SYK earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, SYK beat 33 and missed 7. Revenue for the quarter ended Sep 30, 2026 was $6.52B, up 7.6% from $6.06B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $3.52 | $3.56 | $3.44 - $3.78 | -1.12% | Miss | +10.3% | 25 | 0 up, 14 down | Oct 29, 2026 | $6.52B |
| Jun 30, 2026 | $3.69 | $3.46 | $3.36 - $3.61 | +6.65% | Beat | +17.9% | 24 | 1 up, 1 down | Jul 30, 2026 | $6.59B |
| Mar 31, 2026 | $2.60 | $2.98 | $2.86 - $3.07 | -12.75% | Miss | -8.5% | 24 | 0 up, 3 down | Apr 30, 2026 | $6.02B |
| Dec 31, 2025 | $4.47 | $4.40 | $4.37 - $4.43 | +1.59% | Beat | +11.5% | 24 | 2 up, 1 down | Jan 29, 2026 | $7.17B |
| Sep 30, 2025 | $3.19 | $3.13 | $3.05 - $3.16 | +1.92% | Beat | +11.1% | 26 | 1 up, 1 down | Oct 30, 2025 | $6.06B |
| Jun 30, 2025 | $3.13 | $3.07 | $3.00 - $3.15 | +1.95% | Beat | +11.4% | 26 | 1 up, 2 down | Jul 31, 2025 | $6.02B |
| Mar 31, 2025 | $2.84 | $2.73 | $2.65 - $3.14 | +4.03% | Beat | +13.6% | 26 | 1 up, 4 down | May 1, 2025 | $5.87B |
| Dec 31, 2024 | $4.01 | $3.87 | $3.84 - $3.92 | +3.62% | Beat | +15.9% | 25 | 2 up, 1 down | Jan 28, 2025 | $6.44B |
| Sep 30, 2024 | $2.87 | $2.77 | $2.71 - $2.96 | +3.61% | Beat | +16.7% | 27 | 2 up, 0 down | Oct 29, 2024 | $5.49B |
| Jun 30, 2024 | $2.81 | $2.79 | $2.75 - $2.91 | +0.72% | Beat | +10.6% | 26 | 2 up, 0 down | Jul 30, 2024 | $5.42B |
| Mar 31, 2024 | $2.50 | $2.36 | $2.28 - $2.48 | +5.93% | Beat | +16.8% | 24 | 0 up, 1 down | Apr 30, 2024 | $5.24B |
| Dec 31, 2023 | $3.46 | $3.27 | $3.23 - $3.31 | +5.81% | Beat | +15.3% | 25 | 1 up, 0 down | Jan 30, 2024 | $5.82B |
| Sep 30, 2023 | $2.46 | $2.44 | $2.34 - $2.53 | +0.82% | Beat | +16.0% | 25 | 1 up, 1 down | Nov 2, 2023 | $4.91B |
| Jun 30, 2023 | $2.54 | $2.38 | $2.32 - $2.48 | +6.72% | Beat | +12.9% | 25 | 0 up, 0 down | Aug 3, 2023 | $5.00B |
| Mar 31, 2023 | $2.14 | $2.00 | $1.96 - $2.11 | +7.00% | Beat | +8.6% | 25 | 1 up, 0 down | May 1, 2023 | $4.78B |
| Dec 31, 2022 | $3.00 | $2.84 | $2.76 - $2.92 | +5.63% | Beat | +10.7% | 25 | 2 up, 0 down | Jan 31, 2023 | $5.20B |
| Sep 30, 2022 | $2.12 | $2.23 | $2.14 - $2.34 | -4.93% | Miss | -3.6% | 25 | 1 up, 2 down | Oct 31, 2022 | $4.48B |
| Jun 30, 2022 | $2.25 | $2.28 | $2.17 - $2.36 | -1.32% | Miss | 0.0% | 22 | 1 up, 1 down | Jul 26, 2022 | $4.49B |
| Mar 31, 2022 | $1.97 | $1.92 | $1.85 - $2.15 | +2.60% | Beat | +2.1% | 25 | 0 up, 1 down | Apr 28, 2022 | $4.28B |
| Dec 31, 2021 | $2.71 | $2.72 | $2.69 - $2.80 | -0.37% | Miss | -3.6% | 25 | 0 up, 1 down | Jan 27, 2022 | $4.70B |
| Sep 30, 2021 | $2.20 | $2.28 | $2.03 - $2.50 | -3.51% | Miss | +2.8% | 25 | N/A | Oct 28, 2021 | $4.16B |
| Jun 30, 2021 | $2.25 | $2.13 | $1.88 - $2.26 | +5.63% | Beat | +251.6% | 27 | N/A | Jul 27, 2021 | $4.29B |
| Mar 31, 2021 | $1.93 | $1.98 | $1.88 - $2.20 | -2.53% | Miss | +4.9% | 27 | N/A | Apr 27, 2021 | $3.95B |
| Dec 31, 2020 | $2.81 | $2.55 | $2.34 - $2.68 | +10.20% | Beat | +12.9% | 27 | N/A | Jan 27, 2021 | $4.26B |
| Sep 30, 2020 | $2.14 | $1.43 | $0.91 - $1.88 | +49.65% | Beat | +12.0% | 26 | N/A | Oct 29, 2020 | $3.74B |
| Jun 30, 2020 | $0.64 | $0.57 | -$0.13 - $1.03 | +12.28% | Beat | -67.7% | 22 | N/A | Jul 30, 2020 | $2.76B |
| Mar 31, 2020 | $1.84 | $1.74 | $0.85 - $2.08 | +5.75% | Beat | -2.1% | 15 | N/A | Apr 30, 2020 | $3.59B |
| Dec 31, 2019 | $2.49 | $2.46 | $2.44 - $2.48 | +1.22% | Beat | +14.2% | 25 | N/A | Jan 28, 2020 | $4.13B |
| Sep 30, 2019 | $1.91 | $1.90 | $1.86 - $1.92 | +0.53% | Beat | +13.0% | 26 | N/A | Oct 29, 2019 | $3.59B |
| Jun 30, 2019 | $1.98 | $1.94 | $1.91 - $1.96 | +2.06% | Beat | +12.5% | 28 | N/A | Jul 25, 2019 | $3.65B |
| Mar 31, 2019 | $1.88 | $1.84 | $1.82 - $1.87 | +2.17% | Beat | +11.9% | 29 | N/A | Apr 23, 2019 | $3.52B |
| Dec 31, 2018 | $2.18 | $2.15 | $2.12 - $2.20 | +1.40% | Beat | +11.2% | 30 | N/A | Jan 29, 2019 | $3.80B |
| Sep 30, 2018 | $1.69 | $1.68 | $1.64 - $1.72 | +0.60% | Beat | +11.2% | 26 | N/A | Oct 25, 2018 | $3.24B |
| Jun 30, 2018 | $1.76 | $1.73 | $1.70 - $1.74 | +1.73% | Beat | +15.0% | 25 | N/A | Jul 24, 2018 | $3.32B |
| Mar 31, 2018 | $1.68 | $1.60 | $1.58 - $1.64 | +5.00% | Beat | +13.5% | 26 | N/A | Apr 26, 2018 | $3.24B |
| Dec 31, 2017 | $1.96 | $1.95 | $1.92 - $1.98 | +0.51% | Beat | +10.1% | 25 | N/A | Jan 30, 2018 | $3.47B |
| Sep 30, 2017 | $1.52 | $1.50 | $1.42 - $1.55 | +1.33% | Beat | +9.4% | 26 | N/A | Oct 26, 2017 | $3.01B |
| Jun 30, 2017 | $1.53 | $1.51 | $1.49 - $1.54 | +1.32% | Beat | +10.1% | 26 | N/A | Jul 27, 2017 | $3.01B |
| Mar 31, 2017 | $1.48 | $1.43 | N/A | +3.50% | Beat | +19.4% | N/A | N/A | Apr 25, 2017 | $2.96B |
| Dec 31, 2016 | $1.78 | $1.76 | N/A | +1.14% | Beat | +14.1% | N/A | N/A | Jan 24, 2017 | $3.16B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $13.63, up 11.8% from the year before. It was $5.80 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $13.63 | +11.8% |
| Dec 31, 2024 | $12.19 | +15.0% |
| Dec 31, 2023 | $10.60 | +13.5% |
| Dec 31, 2022 | $9.34 | +2.8% |
| Dec 31, 2021 | $9.09 | +22.3% |
| Dec 31, 2020 | $7.43 | -10.0% |
| Dec 31, 2019 | $8.26 | +13.0% |
| Dec 31, 2018 | $7.31 | +12.6% |
| Dec 31, 2017 | $6.49 | +11.9% |
| Dec 31, 2016 | $5.80 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 10,000 words across 20 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 10,160 | 20 | |
| 2026Q2 | Jun 30, 2026 | 6,886 | 17 | |
| 2026Q1 | Mar 31, 2026 | 9,896 | 21 | |
| 2025Q4 | Dec 31, 2025 | 8,306 | 20 | |
| 2025Q3 | Sep 30, 2025 | 5,794 | 18 | |
| 2025Q2 | Jun 30, 2025 | 7,552 | 16 | |
| 2025Q1 | Mar 31, 2025 | 9,803 | 22 | |
| 2024Q4 | Dec 31, 2024 | 7,461 | 15 |
2026Q3 Earnings Call
Opening remarks
Kevin Lobo Chair and CEO Welcome to Stryker's third quarter earnings call. Joining me today are Preston Wells, CFO; and Nick Mead, Vice President of Investor Relations. Before I begin, I'd like to congratulate Spencer Stiles on his appointment as Stryker's next CEO. Spencer has spent nearly 3 decades at Stryker, helping shape our strategy, strengthen our culture and drive our growth. You will have additional opportunities to hear more from him at various investor events over the next few months, and I am confident we will come away with an even greater appreciation of his capabilities to lead Stryker into the future. For today's call, I'll provide an overview of our performance. Nick will then provide a brief M&A update, followed by Preston with additional details on financial results and guidance. We will then open the call to Q&A. Turning to our third quarter performance. Organic sales growth for the quarter was 7.7% with 9.1% growth in MedSurg and Neurotechnology and 5.9% growth in Orthopaedics. Our Endoscopy and Ortho Tech divisions delivered double-digit performances and Medical also delivered near double-digit growth. While we delivered solid growth in several businesses, our overall results fell short of our expectations. As Preston mentioned during the investor conference in September, we are facing challenges with our Hip and Knee and Peripheral Vascular businesses. Beginning with Hips and Knees, it is now clear that there is a market slowdown. In the U.S., we are seeing slower procedural growth amid affordability concerns from higher insurance premiums and deductibles. We are also observing increased pre-authorization denials, creating additional friction and delaying patient access to treatment. Europe and the Middle East have also remained soft amid regional disruption, strike-related delays and government funding decisions. In addition to the softer market, we have not been winning at our historical rate. 2026 has been an unusual year, marked by the cyber incident in the first quarter and an SAP implementation within our Orthopaedics businesses in July. This is the last of our businesses to go on to SAP. And while the system is functioning well, it has created a distraction for our teams and delayed our visibility of market conditions. Although Mako sales have been strong again this year, we are behind our expectations on new product sales from Mako RPS and Triathlon Gold. The feedback on these innovations is very positive, but the cyber incident and SAP implementation have impacted our commercial execution. We are taking actions to improve competitive conversions and new product adoption. Finally, as a leader in power tools, we are excited about bringing a power hip impaction solution to the market next year, addressing an important product gap in our hip portfolio.
Frequently Asked Questions About SYK
When is Stryker's next earnings date?
Stryker's next earnings report is expected for Jan 27, 2027.
Did SYK beat earnings estimates last quarter?
No. Stryker reported EPS of $3.52 for the quarter ended Sep 30, 2026, below the $3.56 estimate by 1.12%.
What EPS do analysts expect from SYK next quarter?
The consensus EPS estimate for Stryker for the quarter ending Dec 31, 2026 is $5.06 from 28 analysts, with estimates from $4.55 to $5.30.
How often does SYK beat earnings estimates?
Stryker beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +0.74%.
SYK pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts